Aroa Biosurgery Valuation
| ARX Stock | 0.75 0.02 2.60% |
Aroa Biosurgery is overvalued. Aroa Biosurgery shows a prevailing Real Value of USD0.69 per share. The current price of the firm is USD0.75. Our model approximates the value of Aroa Biosurgery from analyzing the firm fundamentals such as Profit Margin of (0.15) %, current valuation of 244.89 M, and Return On Equity of -0.11 as well as examining its technical indicators and probability of bankruptcy.
Price Book 3.0595 | Enterprise Value 244.9 M | Enterprise Value Ebitda (55.94) | Price Sales 3.7453 | Forward PE 39.3701 |
Overvalued
Today
Please note that Aroa Biosurgery's price fluctuation is extremely dangerous at this time. Calculation of the real value of Aroa Biosurgery is based on 3 months time horizon. Increasing Aroa Biosurgery's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Aroa Biosurgery's intrinsic value may or may not be the same as its current market price of 0.75, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.75 | Real 0.69 | Hype 0.74 | Naive 0.8 |
The intrinsic value of Aroa Biosurgery's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Aroa Biosurgery's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Aroa Biosurgery helps investors to forecast how Aroa stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Aroa Biosurgery more accurately as focusing exclusively on Aroa Biosurgery's fundamentals will not take into account other important factors: Aroa Biosurgery Cash |
|
Aroa Biosurgery Total Value Analysis
Aroa Biosurgery is presently anticipated to have takeover price of 244.89 M with market capitalization of 258.68 M, debt of 6.82 M, and cash on hands of . Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the Aroa Biosurgery fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
244.89 M | 258.68 M | 6.82 M |
Aroa Biosurgery Investor Information
About 26.0% of the company shares are held by company insiders. The book value of Aroa Biosurgery was presently reported as 0.28. The company recorded a loss per share of 0.02. Aroa Biosurgery had not issued any dividends in recent years. The entity had 2:1 split on the 1st of June 2018. Based on the key measurements obtained from Aroa Biosurgery's financial statements, Aroa Biosurgery is not in a good financial situation at the present time. It has a very high likelihood of going through financial trouble in February.Aroa Biosurgery Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Aroa Biosurgery has an asset utilization ratio of 62.19 percent. This implies that the Company is making USD0.62 for each dollar of assets. An increasing asset utilization means that Aroa Biosurgery is more efficient with each dollar of assets it utilizes for everyday operations.Aroa Biosurgery Ownership Allocation
Aroa Biosurgery retains a total of 344.9 Million outstanding shares. Aroa Biosurgery retains significant amount of outstanding shares owned by insiders. An insider is usually defined as a CEO, other corporate executive, director, or institutional investor who own at least 10% of the company's outstanding shares. Since such a large part of the company is owned by insiders, it is advisable to analyze if each of these insiders have been buying or selling the stock in recent months. Remember, it does not matter who owns the company or if the company is currently losing money. If the true value of the company is more than the market pays for it currently, you can still have a good investment opportunity.Aroa Biosurgery Profitability Analysis
The company reported the revenue of 63.36 M. Net Loss for the year was (9.75 M) with profit before overhead, payroll, taxes, and interest of 30.3 M.About Aroa Biosurgery Valuation
The stock valuation mechanism determines Aroa Biosurgery's current worth on a daily basis. In general, an absolute valuation approach attempts to find the value of Aroa Biosurgery based exclusively on its fundamental and basic technical indicators. As compared to an absolute model, our relative valuation model uses a comparative analysis of Aroa Biosurgery. We calculate exposure to Aroa Biosurgery's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Aroa Biosurgery's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 62.2 M | 65.3 M |
Additional Tools for Aroa Stock Analysis
When running Aroa Biosurgery's price analysis, check to measure Aroa Biosurgery's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Aroa Biosurgery is operating at the current time. Most of Aroa Biosurgery's value examination focuses on studying past and present price action to predict the probability of Aroa Biosurgery's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Aroa Biosurgery's price. Additionally, you may evaluate how the addition of Aroa Biosurgery to your portfolios can decrease your overall portfolio volatility.